Home
About
Overview
Sharing Data
ORCID
Help
History (8)
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Synaptic activity regulates AMPA receptor trafficking through different recycling pathways.
Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.
Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
See All 8 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Ther Adv Med Oncol. 2016 Sep; 8(5):351-9.
View in:
PubMed
authors with profiles
Rita Nanda